Brief communication
False-Positive Secretin Stimulation Test for Gastrinoma Associated With the Use of Proton Pump Inhibitor Therapy

https://doi.org/10.1016/j.cgh.2009.02.018Get rights and content

We report the case of a 22-year-old woman who was referred for evaluation of possible Zollinger–Ellison syndrome because of hypergastrinemia and a positive secretin stimulation test. She was being treated with proton pump inhibitors (PPIs) for severe gastroesophageal reflux disease during her initial evaluation. At cessation of PPI therapy, her fasting serum gastrin levels normalized, as did her response to secretin injection. Previous reports describing false-positive secretin tests have been limited to cases of hypergastrinemia in the setting of chronic atrophic gastritis, presumably a result of achlorhydria. This case represents a clearly documented instance of PPI-related hypergastrinemia with a false-positive secretin test, with subsequent normalization of serum gastrin and a negative secretin test after withdrawal of PPI therapy. The current case emphasizes the need to assess the acid secretory status of individuals with hypergastrinemia and to discontinue the use of potent antisecretory agents, principally PPIs, to avoid the erroneous diagnosis of gastrinoma and before embarking on expensive and potentially invasive evaluations for the purpose of tumor localization.

Section snippets

Discussion

As a hallmark of ZES, hypergastrinemia is considered the most sensitive and specific finding for the identification of patients with this disorder.1 However, hypergastrinemia also may occur in patients with several other conditions and most commonly is associated with achlorhydria caused by chronic atrophic gastritis in the setting of long-standing H pylori infection or with autoimmune disorders, such as pernicious anemia, alopecia areata, Sjögren's syndrome, and Hashimoto's thyroiditis.2, 3, 4

References (19)

  • J.E. McGuigan

    Zollinger–Ellison syndrome and other hypersecretory states

  • S.J. Brand et al.

    Reciprocal regulation of antral gastrin and somatostatin gene expression by omeprazole-induced achlorhydria

    J Clin Invest

    (1988)
  • M.M. Wolfe et al.

    Zollinger–Ellison syndrome: current concepts in diagnosis and treatment

    N Engl J Med

    (1987)
  • E. Lahner et al.

    Occurrence and risk factors for autoimmune thyroid disease in patients with atrophic body gastritis

    Am J Med

    (2008)
  • M.M. Wolfe et al.

    Inhibition of gastrin release by secretin is mediated by somatostatin in cultured rat antral mucosa

    J Clin Invest

    (1983)
  • M. Komasaka et al.

    Antisecretory effect of somatostatin on gastric acid via inhibition of histamine release in isolated mouse stomach

    Eur J Pharmacol

    (2002)
  • P.S. Karnik et al.

    Inhibition of gastrin gene expression by somatostatin

    J Clin Invest

    (1989)
  • P.S. Karnik et al.

    Somatostatin stimulates gastrin mRNA turnover in dog antral mucosa

    J Biol Chem

    (1990)
  • H. Frucht et al.

    Secretin and calcium provocative tests in the Zollinger–Ellison syndromeA prospective study

    Ann Intern Med

    (1989)
There are more references available in the full text version of this article.

Cited by (0)

Conflicts of interest The authors disclose no conflicts.

View full text